Orally disintegrating film agent composition as well as preparation method and application thereof
By using specific film-forming materials and disintegrating agents in oral disintegrating film agents, the problems of poor film-forming performance and long disintegration time of drug oral film agents are solved, and the rapid disintegration and efficient absorption of drugs in the oral cavity are achieved. , improves drug delivery compliance and therapeutic effect.
Patent Information
- Application Number
- CN202411129296.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-16
- Publication Date
- 2024-11-12
AI Technical Summary
The oral film agents of existing drugs have problems such as poor film formation performance and long disintegration time, which affects the drug delivery compliance and therapeutic effect.
Oral disintegration using a combination of pharmaceutical active ingredients, film-forming materials (such as polyvinyl alcohol, polyoxyethylene, povidone, plulandosac) and disintegrants (such as sodium carboxymethyl starch, pregelatinized starch) Film agents, by reasonably adjusting the ratio of film forming materials to the active ingredients of the drug and the disintegrant, the disintegration time is controlled within ≤30 seconds, and the film forming performance and disintegration speed are improved.
It significantly shortens the disintegration time of the drug in the oral cavity, improves the oral compliance and therapeutic effect of the drug, and is suitable for the administration of drugs such as dyfaline, tacrolimus and carriparazine.
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure SMS_3
Abstract
Description
Technical Field
[0001] The present application relates to the technical field of pharmaceutical preparations, and in particular to an orally disintegrating film composition and a preparation method and application thereof. Background Art
[0002] Oral film refers to a film preparation obtained by processing the raw material drug with a suitable film-forming material. It can be used orally or on the mucosa. Compared with traditional oral dosage forms, it has the characteristics of good compliance, does not require drinking water to be taken, and can be quickly dissolved when placed in the mouth. It is suitable for children, the elderly or patients with swallowing difficulties.
[0003] However, most drugs currently still use traditional oral dosage forms such as capsules and tablets, or use more inconvenient injection dosage forms. For example, difacillin, as a new type of highly selective κ receptor agonist acting on the periphery, can exert an antipruritic effect by activating κ opioid receptors on peripheral neurons and immune cells. Its marketed dosage form is an injection solution, which is administered by intravenous injection. The administration route is single and inconvenient. Tacrolimus is the first choice immunosuppressive drug for liver and kidney transplant patients. It can also be used for patients with rejection reactions after liver and kidney transplantation who are resistant to traditional immunosuppressive regimens. Its marketed dosage forms include capsules, sustained-release capsules, ointments, etc., but there is still a problem of poor compliance.
[0004] Furthermore, even though some drugs adopt oral film dosage forms, such as cariprazine oral film dosage forms, such oral film dosage forms still have a long disintegration time in the oral cavity (the disintegration time in the oral cavity is greater than 1 minute, or even 2 minutes), and in actual clinical use, the purpose of improving the patient's compliance with medication is still not achieved. At the same time, the long disintegration time of the film dosage form in the oral cavity will also cause the film to clump and adhere, affecting the efficacy of the drug and the therapeutic effect.
[0005] Therefore, how to prepare oral film dosage forms of drugs and make them have better film-forming properties and shorter disintegration time is an urgent problem to be solved. Summary of the invention
[0006] Based on this, the present application provides an orally disintegrating film composition having good film-forming properties and short disintegration time.
[0007] In a first aspect of the present application, there is provided an orally disintegrating film composition, comprising a pharmaceutically active ingredient, a film-forming material and a disintegrant;
[0008] The film-forming material comprises one or more of polyvinyl alcohol, polyoxyethylene, povidone, copovidone and pullulan; the disintegrant comprises one or more of sodium carboxymethyl starch and pregelatinized starch.
[0009] In some of the embodiments, the orally disintegrating film composition has a disintegration time in the oral cavity of ≤30 s; alternatively, the disintegration time is ≤20 s; alternatively, the disintegration time is ≤10 s.
[0010] In some embodiments, the active pharmaceutical ingredient includes difacoum, tacrolimus, cariprazine or pharmaceutically acceptable salts or inclusion compounds thereof.
[0011] In some embodiments, the active pharmaceutical ingredient is cariprazine, and the orally disintegrating film composition has at least one of the following characteristics:
[0012] (1) The mass ratio of the film-forming material to the active pharmaceutical ingredient is 1:1 to 5:1;
[0013] (2) The mass ratio of the disintegrant to the active pharmaceutical ingredient is 1:1 to 5:1.
[0014] In some embodiments, the pharmaceutically active ingredient is cariprazine, and the orally disintegrating film composition further comprises a pH regulator, wherein the pH regulator makes the pH of the orally disintegrating film composition be between 7 and 11; and / or
[0015] The active pharmaceutical ingredient is cariprazine, and the particle size D90 of the active pharmaceutical ingredient is 20 μm to 50 μm.
[0016] In some embodiments, the active pharmaceutical ingredient is cariprazine, and the orally disintegrating film composition further comprises a taste masking agent, wherein the taste masking agent has at least one of the following characteristics:
[0017] (1) The taste masking agent includes one or more of sulfobutyl-β-cyclodextrin and hydroxypropyl-β-cyclodextrin;
[0018] (2) The molar ratio of the taste masking agent to the active ingredient of the drug is 2:1 to 5:1.
[0019] In some embodiments, the active pharmaceutical ingredient is difacoum, and the orally disintegrating film composition has at least one of the following characteristics:
[0020] (1) The mass ratio of the film-forming material to the active pharmaceutical ingredient is 45:1 to 235:1;
[0021] (2) The mass ratio of the disintegrant to the active pharmaceutical ingredient is 45:1 to 235:1.
[0022] In some embodiments, the active pharmaceutical ingredient is tacrolimus, and the orally disintegrating film composition has at least one of the following characteristics:
[0023] (1) The mass ratio of the film-forming material to the active pharmaceutical ingredient is 3:1 to 15:1;
[0024] (2) The mass ratio of the disintegrant to the active pharmaceutical ingredient is 3:1 to 15:1.
[0025] The second aspect of the present application provides a method for preparing the orally disintegrating film composition of the first aspect, comprising the following steps:
[0026] Mixing the active pharmaceutical ingredient, film-forming material and disintegrant with water to prepare a mixed solution;
[0027] The mixed solution is degassed and film-formed to prepare an oral film preparation of the drug.
[0028] The third aspect of the present application provides the use of the orally disintegrating film composition described in the first aspect in the preparation of a drug with antipruritic, immunosuppressive or antidepressant effects.
[0029] The present application adopts a combination of suitable film-forming materials and disintegrants, so that the prepared orally disintegrating film composition has good film-forming properties and can significantly shorten the oral disintegration time of the drug, which is beneficial to improving the oral compliance of the drug. DETAILED DESCRIPTION
[0030] The orally disintegrating film composition of the present application and its preparation method and application are further described in detail below in conjunction with specific examples. The present application can be implemented in many different forms and is not limited to the embodiments described herein. On the contrary, the purpose of providing these embodiments is to make the understanding of the disclosure of the present application more thorough and comprehensive.
[0031] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art to which this application belongs. The terms used herein in the specification of this application are only for the purpose of describing specific embodiments and are not intended to limit this application.
[0032] As used herein, "one or more" refers to any one, any two, or any two or more of the listed items.
[0033] In this application, "first aspect", "second aspect", "third aspect", etc. are used only for descriptive purposes and cannot be understood as indicating or implying relative importance or quantity, nor can they be understood as implicitly indicating the importance or quantity of the indicated technical features. Moreover, "first", "second", "third", etc. only serve the purpose of non-exhaustive enumeration and description, and it should be understood that they do not constitute a closed limitation on quantity.
[0034] In the present application, the technical features described in an open manner include closed technical solutions composed of the listed features, and also include open technical solutions containing the listed features.
[0035] In this application, when it comes to numerical ranges, unless otherwise specified, the above numerical ranges are deemed to be continuous and include the minimum and maximum values of the range, as well as each value between such minimum and maximum values. Further, when a range refers to an integer, each integer between the minimum and maximum values of the range is included. In addition, when multiple ranges are provided to describe features or characteristics, the ranges can be merged. In other words, unless otherwise specified, all ranges disclosed herein should be understood to include any and all subranges included therein.
[0036] The percentage contents involved in this application, unless otherwise specified, refer to mass percentage for solid-liquid mixing and solid-solid mixing, and refer to volume percentage for liquid-liquid mixing.
[0037] The percentage concentrations mentioned in this application, unless otherwise specified, refer to the final concentration, which refers to the percentage of the added component in the system after the addition of the component.
[0038] The temperature parameters in this application, unless otherwise specified, allow for both constant temperature treatment and treatment within a certain temperature range. The constant temperature treatment allows the temperature to fluctuate within the accuracy range of instrument control.
[0039] The room temperature in this application generally refers to 4°C~30°C, preferably 20±5°C.
[0040] Some examples of the present application provide an orally disintegrating film composition, characterized in that it includes a pharmaceutically active ingredient, a film-forming material and a disintegrant; the film-forming material includes one or more of polyvinyl alcohol, polyoxyethylene, povidone, copovidone and pullulan; the disintegrant includes one or more of sodium carboxymethyl starch and pregelatinized starch.
[0041] Furthermore, the film-forming material includes polyvinyl alcohol, so that the oral film has better film-forming properties and a uniform film layer.
[0042] Furthermore, the disintegrant includes sodium carboxymethyl starch, which can further shorten the disintegration time of the oral film in the oral cavity without affecting the film-forming performance.
[0043] In some examples, the oral disintegration time of the orally disintegrating film composition is less than 30 s, further, the oral disintegration time is ≤20 s, and further, the oral disintegration time is ≤10 s.
[0044] In addition, for different active pharmaceutical ingredients, reasonable control of the mass ratio of the film-forming material to the active pharmaceutical ingredient can make the oral film have better film-forming properties, a uniform film layer, and a shorter disintegration time.
[0045] In some examples, the active pharmaceutical ingredient is cariprazine, and the mass ratio of the film-forming material to the active pharmaceutical ingredient is 1:1 to 5:1. Specifically, the mass ratio of the film-forming material to the active pharmaceutical ingredient includes, but is not limited to, 1:1, 2:1, 3:1, 4:1, 5:1, or any two of the foregoing.
[0046] In some examples, the active pharmaceutical ingredient is dimethoate, and the mass ratio of the film-forming material to the active pharmaceutical ingredient is 45:1 to 235:1. Specifically, the mass ratio of the film-forming material to the active pharmaceutical ingredient includes but is not limited to: 45:1, 48:1, 55:1, 80:1, 100:1, 130:1, 135:1, 140:1, 150:1, 180:1, 200:1, 220:1, 230:1, 235:1 or any two of the foregoing.
[0047] In some examples, the pharmaceutically active ingredient is tacrolimus, and the mass ratio of the film-forming material to the pharmaceutically active ingredient is 3:1 to 15:1. Specifically, the mass ratio of the film-forming material to the pharmaceutically active ingredient includes, but is not limited to, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 11:1, 12:1, 13:1, 14:1, 15:1, or any two of the foregoing.
[0048] In addition, for different active pharmaceutical ingredients, reasonable control of the mass ratio of the disintegrant to the active pharmaceutical ingredient can make the oral film have better film-forming properties, a uniform film layer, and a shorter disintegration time.
[0049] In some examples, the active pharmaceutical ingredient is cariprazine, and the mass ratio of the disintegrant to the active pharmaceutical ingredient is 1:1 to 5:1. Specifically, the mass ratio of the disintegrant to the active pharmaceutical ingredient includes, but is not limited to, 1:1, 2:1, 3:1, 4:1, 5:1, or any two of the foregoing.
[0050] In some examples, the active pharmaceutical ingredient is difacillin, and the mass ratio of the disintegrant to the active pharmaceutical ingredient is 45:1 to 235:1. Specifically, the mass ratio of the disintegrant to the active pharmaceutical ingredient includes but is not limited to: 45:1, 48:1, 55:1, 80:1, 100:1, 130:1, 135:1, 140:1, 150:1, 180:1, 200:1, 220:1, 230:1, 235:1 or any two of the foregoing.
[0051] In some examples, the pharmaceutically active ingredient is tacrolimus, and the mass ratio of the disintegrant to the pharmaceutically active ingredient is 3:1 to 15:1. Specifically, the mass ratio of the disintegrant to the pharmaceutically active ingredient includes, but is not limited to, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 11:1, 12:1, 13:1, 14:1, 15:1 or any two of the foregoing.
[0052] In addition, cariprazine has a more obvious bitter taste. After being prepared into an oral film, it disintegrates in the mouth. Due to the large contact area, the bitter taste becomes more obvious, while the taste-masking effect of traditional oral films is poor. Therefore, in order to further improve patients' compliance with medication, especially younger patients, it is necessary to study the taste-masking properties of oral films.
[0053] Based on this, the present application has found that, based on the research on improving the taste-masking properties of the oral film dosage form of cariprazine, on the one hand, a significant taste-masking effect can be achieved by adjusting the particle size of the API and the pH of the system; on the other hand, a significant taste-masking effect can be achieved by adding a specific taste-masking agent and reasonably controlling the amount added.
[0054] In some examples, the composition of the orally disintegrating film composition also includes a pH regulator, and the pH regulator makes the pH of the orally disintegrating film composition be 7 to 11. Specifically, the pH of the orally disintegrating film composition includes but is not limited to: 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11 or any two of the foregoing. Without limitation, the pH of the orally disintegrating film composition can be detected by the following method: weigh 200 mg of the oral film, place it in 20 mL of purified water, let it stand and dissolve for 10 minutes, and take the supernatant to detect the pH value. Without limitation, the pH regulator includes but is not limited to: sodium dihydrogen phosphate or, disodium hydrogen phosphate or sodium hydroxide.
[0055] In some examples, the particle size D90 of the active pharmaceutical ingredient is 20 μm to 50 μm. Specifically, the particle size D90 of the active pharmaceutical ingredient includes but is not limited to: 20 μm, 25 μm, 30 μm, 35 μm, 40 μm, 45 μm, 50 μm, or any two of the foregoing.
[0056] In some examples, the composition of the orally disintegrating film composition further includes a taste masking agent. Further, the taste masking agent includes one or more of sulfobutyl-β-cyclodextrin and hydroxypropyl-β-cyclodextrin. Further, the taste masking agent includes sulfobutyl-β-cyclodextrin.
[0057] In some examples, the molar ratio of the taste masking agent to the active pharmaceutical ingredient is 2: 1 to 5: 1. Specifically, the molar ratio of the taste masking agent to the active pharmaceutical ingredient includes but is not limited to: 2: 1, 2.5: 1, 3: 1, 3.5: 1, 4: 1, 4.5: 1, 5: 1 or any two of the foregoing.
[0058] In some examples, the taste masking agent further comprises sucralose. Without limitation, the mass ratio of sucralose to the active pharmaceutical ingredient is 1:(0.05-3). Specifically, the mass ratio of sucralose to the active pharmaceutical ingredient includes, but is not limited to, 1:0.05, 1:0.06, 1:0.07, 1:0.1, 1:0.5, 1:1, 1:1.5, 1:2, 1:2.5, 1:3, 1:3.5, 1:4, 1:4.5, 1:5 or any two of the foregoing.
[0059] In addition, in some of the examples, the composition of the oral film of the drug also includes a plasticizer. By introducing a specific plasticizer, the preparation of the oral film is facilitated, making it easy to demould and not easy to curl. Further, the plasticizer includes triethyl citrate (TEC).
[0060] Other examples of the present application provide a method for preparing the orally disintegrating film composition as described above, comprising the following steps:
[0061] Mixing the active pharmaceutical ingredient, film-forming material and disintegrant with water to prepare a mixed solution;
[0062] The mixed solution is degassed and film-formed to prepare an oral film preparation of the drug.
[0063] In some of the examples, the degassing conditions include: centrifugal degassing, and a centrifugal speed of ≥2000rpm / min.
[0064] In some of the examples, film-forming conditions include: film-forming by coating, a material conveying speed of 1 m / min to 1.5 m / min, and a drying temperature of 90° C. to 100° C.
[0065] Other examples of the present application provide use of the orally disintegrating film composition as described above in the preparation of a drug having antipruritic, immunosuppressive or antidepressant effects.
[0066] Chronic kidney disease-associated pruritus (CKD-aP) is a common symptom that causes severe pain to patients. 50% of CKD-aP patients have systemic pruritus, while other patients mainly affect the back, face and arms. The incidence of CKD-aP in dialysis patients is as high as 70%, of which about 40% have moderate or severe systemic pruritus. The latest data from the ITCH National Registry Study show that about 59% of patients with pruritus experience symptoms every day or almost every day, and most patients have symptoms that last for months or years. There is currently no unified standard regimen internationally, and commonly used antipruritic treatments, such as antihistamines and corticosteroids, cannot provide sustained and adequate relief. Moderate to severe chronic pruritus has been repeatedly shown to be closely associated with sleep disorders, depression and mortality risk, seriously reducing the quality of life of patients. The specific pathogenesis of CKD-aP has not yet been clarified, and there are two main hypotheses: the immune-inflammatory hypothesis and the opioid hypothesis. The opioid hypothesis believes that uremic pruritus is related to the overexpression of opioid μ-receptors in the body's dermal cells and lymphocytes. Difacillin is a novel, highly selective κ receptor agonist that acts on the periphery, and mainly exerts an antipruritic effect by activating κ opioid receptors on peripheral neurons and immune cells. Because it only acts on the periphery and rarely penetrates the blood-brain barrier, it does not cause adverse reactions such as addiction and respiratory depression. At present, difacillin is mainly an injection. The oral film of difacillin provided in this application can be swallowed without water, providing CKD patients with a new method of administration, especially helping moderate to severe patients to control their water intake and reduce the risk of water and sodium retention. At the same time, the oral film is small in size, easy to carry, and can be administered orally, reducing the risk of infection caused by administration by injection.
[0067] Tacrolimus is a fermentation product isolated from Streptomyces. It is a macrolide antibiotic and a powerful new immunosuppressant. It mainly inhibits the release of interleukin-2 (IL-2) and comprehensively inhibits the action of T lymphocytes. It is 100 times stronger than cyclosporine (CsA). In recent years, it has been marketed in 14 countries including Japan and the United States as a first-line drug for liver and kidney transplantation. Clinical trials have shown that it has a good effect in transplantation of heart, lung, intestine, bone marrow, etc. At the same time, FK506 also plays an active role in the treatment of autoimmune diseases such as atopic dermatitis (AD), systemic lupus erythematosus (SLE), and autoimmune eye diseases. Tacrolimus oral capsules, sustained-release capsules, etc. are the first choice immunosuppressive drugs for patients with liver, heart, kidney and bone marrow transplantation. This drug can also be used for patients with post-transplant rejection reactions that are resistant to traditional immunosuppressive regimens. Currently, there is no public oral film of tacrolimus. The oral film of tacrolimus provided in the present application can be swallowed without water, providing a new dosing method option for patients with immune rejection. In addition, the oral film is small in size and easy to carry.
[0068] Cariprazine generally refers to cariprazine hydrochloride, which is a once-daily atypical antipsychotic developed by AbbVie. Pharmacodynamic studies have shown that it may act as a partial agonist with high affinity for dopamine D3, dopamine D2 and 5-hydroxytryptamine 5-HT1A receptors, and can also be used as an adjunctive treatment for patients with major depression who are receiving antidepressant treatment.
[0069] For experimental parameters not specified in the following specific embodiments, reference is made to the instructions given in the present application document, and reference may also be made to experimental manuals in the art or other experimental methods known in the art, or to experimental conditions recommended by manufacturers.
[0070] The raw materials and reagents involved in the following specific examples can be obtained from commercial sources, or can be prepared by those skilled in the art according to known methods.
[0071] Examples (S) 1-4 and Comparative Examples (D) 1-3 investigated the effect of the type of film-forming material in the oral disintegrating film of cariprazine. The formulations and test results are shown in Table 1 below:
[0072] Table 1
[0073]
[0074] Note: LOD refers to loss on drying, which is measured using a rapid moisture analyzer at 105°C in free drying mode.
[0075] The preparation method of the oral disintegrating film of cariprazine is as follows:
[0076] (1) Liquid preparation: Weigh about 3 to 5 times the weight of the dry material in the prescription with purified water, heat it to 60°C to 70°C, add the film-forming material and stir until completely dissolved, then cool to room temperature. Then add the plasticizer and taste masking agent in turn and stir evenly. Add the API and stir and disperse for at least 5 minutes.
[0077] (2) Degassing: The solution obtained in step 1 is degassed by a vacuum centrifugal degassing machine at a centrifugal speed of not less than 2000 rpm / min.
[0078] (3) Film making: Start the coating film making machine, set appropriate parameters, the conveying speed is 1-1.5 m / min, the drying temperature is 90°C-100°C, and the solution obtained in step (2) is added to the feed port of the film making machine to start film making.
[0079] Examples (S) 5 to 11 investigate the effects of film-forming materials, disintegrant types and proportions in the oral disintegrating film of cariprazine. The formulations and test results are shown in Table 2 below:
[0080] Table 2
[0081]
[0082] The preparation method of the oral disintegrating film of cariprazine is the same as that of the above embodiment.
[0083] Examples (S) 12 to 20 investigate the effects of pH value and active ingredient particle size in the oral disintegrating film of cariprazine. The formulations and test results are shown in Table 3 below:
[0084] Table 3
[0085]
[0086] The preparation method of the above-mentioned oral disintegrating film of cariprazine is the same as the above-mentioned embodiment, wherein the different pH values in Examples 12-16 are adjusted by adding a pH adjuster (sodium dihydrogen phosphate, disodium hydrogen phosphate or sodium hydroxide) into the preparation solution.
[0087] Examples (S) 21 to 28 investigated the effects of the type and ratio of taste masking agents in the oral disintegrating film of cariprazine. The formulations and test results are shown in Table 4 below:
[0088] Table 4
[0089]
[0090] The preparation method of the oral disintegrating film of cariprazine is the same as that of the above embodiment.
[0091] Examples (S) 29-32 and Comparative Examples (D) 4-5 investigated the effect of the type of film-forming material in the oral disintegrating film of difacillin acetate. The formulations and test results are shown in Table 5 below:
[0092] Table 5
[0093]
[0094] The preparation method of the oral disintegrating film of difacillin acetate is the same as that of the above embodiment.
[0095] Examples (S) 33 to 39 investigate the effects of film-forming materials, disintegrant types and ratios in oral disintegrating films of difacillin acetate. The formulations and test results are shown in Table 6 below:
[0096] Table 6
[0097]
[0098] The preparation method of the oral disintegrating film of difacillin acetate is the same as that of the above embodiment.
[0099] Examples (S) 40-43 and Comparative Examples (D) 6-7 investigated the effect of the type of film-forming material in the oral disintegrating film of tacrolimus. The formulations and test results are shown in Table 7 below:
[0100] Table 7
[0101]
[0102] The preparation method of the above-mentioned tacrolimus orally disintegrating film is the same as that in the above-mentioned embodiment.
[0103] Examples (S) 44 to 50 investigated the effects of film-forming materials, disintegrant types and ratios in the oral disintegrating film of tacrolimus. The formulations and test results are shown in Table 8 below:
[0104] Table 8
[0105]
[0106] The preparation method of the above-mentioned tacrolimus orally disintegrating film is the same as that in the above-mentioned embodiment.
[0107] The technical features of the above-described embodiments may be arbitrarily combined. To make the description concise, not all possible combinations of the technical features in the above-described embodiments are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.
[0108] The above-described embodiments only express several implementation methods of the present application, which is convenient for understanding the technical solution of the present application in detail, but it cannot be understood as limiting the scope of protection of the patent application. It should be pointed out that for ordinary technicians in this field, without departing from the concept of the present application, several modifications and improvements can be made, which all belong to the scope of protection of the present application. It should be understood that the technical solutions obtained by those skilled in the art through logical analysis, reasoning or limited experiments on the basis of the technical solutions provided in the present application are all within the scope of protection of the claims attached to the present application. Therefore, the scope of protection of the patent of this application shall be based on the content of the attached claims, and the description can be used to interpret the content of the claims.
Claims
1. An orally disintegrating film composition, characterized in that: The invention comprises active pharmaceutical ingredients, film-forming materials and disintegrants; the film-forming materials comprise one or more of polyvinyl alcohol, polyoxyethylene, povidone, copovidone and pullulan; and the disintegrants comprise one or more of sodium carboxymethyl starch and pregelatinized starch.
2. The orally disintegrating film composition according to claim 1, characterized in that The orally disintegrating film composition has a disintegration time in the oral cavity of ≤30 s; optionally, the disintegration time is ≤20 s; optionally, the disintegration time is ≤10 s.
3. The orally disintegrating film composition according to claim 1 or 2, characterized in that: The active pharmaceutical ingredients include difacillin, tacrolimus, cariprazine or pharmaceutically acceptable salts and inclusion compounds thereof.
4. The orally disintegrating film composition according to claim 3, characterized in that: The active pharmaceutical ingredient is cariprazine, and the orally disintegrating film composition has at least one of the following characteristics: (1) The mass ratio of the film-forming material to the active pharmaceutical ingredient is 1:1 to 5:1; (2) The mass ratio of the disintegrant to the active pharmaceutical ingredient is 1:1 to 5:
1.
5. The orally disintegrating film composition according to claim 3, characterized in that: The active pharmaceutical ingredient is cariprazine, and the orally disintegrating film composition further comprises a pH regulator, wherein the pH of the orally disintegrating film composition is adjusted to 7 to 11 by the pH regulator; and / or The active pharmaceutical ingredient is cariprazine, and the particle size D90 of the active pharmaceutical ingredient is 20 μm to 50 μm.
6. The orally disintegrating film composition according to claim 3, characterized in that: The active pharmaceutical ingredient is cariprazine, and the orally disintegrating film composition further comprises a taste masking agent, wherein the taste masking agent has at least one of the following characteristics: (1) The taste masking agent includes one or more of sulfobutyl-β-cyclodextrin and hydroxypropyl-β-cyclodextrin; (2) The molar ratio of the taste masking agent to the active ingredient of the drug is 2:1 to 5:
1.
7. The orally disintegrating film composition according to claim 3, characterized in that: The active ingredient of the drug is difacillin, and the orally disintegrating film composition has at least one of the following characteristics: (1) The mass ratio of the film-forming material to the active pharmaceutical ingredient is 45:1 to 235:1; (2) The mass ratio of the disintegrant to the active pharmaceutical ingredient is 45:1 to 235:
1.
8. The orally disintegrating film composition according to claim 3, characterized in that: The active pharmaceutical ingredient is tacrolimus, and the orally disintegrating film composition has at least one of the following characteristics: (1) The mass ratio of the film-forming material to the active pharmaceutical ingredient is 3:1 to 15:1; (2) The mass ratio of the disintegrant to the active pharmaceutical ingredient is 3:1 to 15:
1.
9. The method for preparing the orally disintegrating film composition according to any one of claims 1 to 8, characterized in that: The steps include: Mixing the active pharmaceutical ingredient, film-forming material and disintegrant with water to prepare a mixed solution; The mixed solution is degassed and film-formed to prepare an oral film preparation of the drug.
10. Use of the orally disintegrating film composition according to any one of claims 1 to 8 in the preparation of a drug having antipruritic, immunosuppressive or antidepressant effects.
Citation Information
Cited By
Oral thin film for the administration of cariprazine
EP4810016A1
Oral thin film for the administration of cariprazine
WO2026195867A1
